OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research
OncologySTAT Marks 1-Year Anniversary with Expert Physician Commentaries on Recent Cancer Research and Practice Developments
New York, NY, Sept. 9, 2008 – OncologySTAT, a free web site featuring high-quality, scientifically based research and cancer care information for oncologists and other healthcare professionals, today celebrated its one-year anniversary by releasing a list of the most influential oncology developments of the past year chosen by an expert physician panel. Two overriding themes of this unique online editorial feature are biomarker-directed treatment decisions and the growing clinical role of personalized medicine.
OncologySTAT’s expert panel includes 12 of the most influential names in hematology and oncology, including two past-presidents of the American Society of Clinical Oncology (ASCO). Based on their expertise and experience, this distinguished group identified the developments with the greatest potential for shaping the future direction of oncology.
“The story of biomarkers reverberates across various tumor types and offers a new paradigm for cancer treatment,” says Lee Schwartzberg, M.D., F.A.C.P., OncologySTAT’s Editor-in-Chief. “Cancer care professionals will benefit from a review of this and other top cancer developments generated collaboratively by OncologySTAT’s panel of the world’s leading oncologists and made accessible through links to original research and expert commentary on OncologySTAT.”
The advisors’ top story choices reflect a trend toward tumor subtype analysis and treatments based on both traditional markers and new biomarkers. “Where oncologists used to prescribe chemotherapy for all cancer patients, they now hunt for biomarkers to ensure they can match the cancer patient with the most appropriate, cost-effective treatments,” says Axel Grothey, M.D., OncologySTAT’s Associate Editor.
“The path toward such types of cancer treatment won’t be easy. Oncologists who pursue personalized medicine face challenges related to logistics, handling of tumor specimens, and testing of individualized treatments in clinical trials,” notes Dr. Grothey. “Still, OncologySTAT’s expert panel expects genetic mutations and biomarkers to have a growing role in treating more common cancer types such as lung cancer. Eventually, oncologists will pay less attention to a patient’s cancer type than to genetic changes and other types of tumor markers.”
Leading Professional Online Resource
Oncologists turn to OncologySTAT to find scientific evidence on new and emerging developments such as biomarker-directed treatment. The top stories of the year selected by OncologySTAT’s expert advisors illustrate the high level of scientific research within the oncology community, as well as the importance of OncologySTAT as a convenient, free online resource for the best available oncology journals and articles.
OncologySTAT has secured more than 16,000 registrants since its launch in September 2007. Backed by the support of major healthcare and pharmaceutical companies, the site has successfully captured more than 30% of US oncologists and hematologists as they actively seek clinical oncology information online. As physicians and other healthcare professionals involved in cancer care now comprise 80% of site users, OncologySTAT has emerged as one of the most trusted and trafficked professional websites in oncology.
“OncologySTAT is proud to promote state-of-the-art cancer care by providing oncology professionals with instant online access to the highest-quality news, expert opinion and clinical information available,” said Monique Fayad, Senior Vice President at Elsevier and Publisher, OncologySTAT. “Only by having the latest scientific evidence at their fingertips can oncologists and other cancer care professionals deliver the quality care that cancer patients and their families need and expect."
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 212 462 1912